Literature DB >> 19427595

Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals receiving highly active antiretroviral therapy.

Maria J Míguez-Burbano1, John E Lewis, Robert Malow.   

Abstract

This longitudinal study examined the impact of alcohol consumption (88 hazardous and 76 nonhazardous drinkers) and race/ethnicity on lipid profiles in individuals starting highly active antiretroviral therapy (HAART). At baseline, Whites and Hispanics had the most adverse lipid profiles, whereas Blacks had the least atherogenic. Whites and Hispanics showed higher increases in cholesterol (W = 11%; H = 6%), triglycerides (W = 40%; H = 24%), and low-density lipoprotein (10%) than Blacks (cholesterol = 4%; triglycerides = 9%; low-density lipoprotein = 4%). Hazardous alcohol consumption was correlated with increased lipids in each group. Hispanics had a clear trait risk for hypertriglyceridemia with HAART (1.9-fold) and with hazardous drinking (3.2-fold; p = .04). The highest risk for hypertriglyceridemia was found in heavy drinkers (3.75-fold; p = .05). Results underscore the importance of an alcohol/race interactive effect on HAART-associated dyslipidemia and the need for assessment and treatment of alcohol disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427595      PMCID: PMC4933314          DOI: 10.1016/j.jana.2009.02.004

Source DB:  PubMed          Journal:  J Assoc Nurses AIDS Care        ISSN: 1055-3290            Impact factor:   1.354


  22 in total

1.  Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study.

Authors:  J P Després; C Couillard; J Gagnon; J Bergeron; A S Leon; D C Rao; J S Skinner; J H Wilmore; C Bouchard
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

2.  Abdominal fat distribution and metabolic risk factors: effects of race.

Authors:  J C Lovejoy; J A de la Bretonne; M Klemperer; R Tulley
Journal:  Metabolism       Date:  1996-09       Impact factor: 8.694

3.  An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.

Authors:  J Fauvel; E Bonnet; J B Ruidavets; J Ferrières; A Toffoletti; P Massip; H Chap; B Perret
Journal:  AIDS       Date:  2001-12-07       Impact factor: 4.177

4.  Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.

Authors:  Maria Luisa Montes; Federico Pulido; Carlos Barros; Emilia Condes; Rafael Rubio; Concepción Cepeda; Fernando Dronda; Antonio Antela; José Sanz; Enrique Navas; Pilar Miralles; Juan Berenguer; Susana Pérez; Angeles Zapata; Juan J González-García; Jose Ma Peña; J J Vázquez; Jose R Arribas
Journal:  J Antimicrob Chemother       Date:  2005-03-10       Impact factor: 5.790

5.  Racial differences in serum lipids in HIV+ women treated with protease inhibitor regimens.

Authors:  Linda L Bausserman; Karen T Tashima; Melissa DiSpigno; Denise Maceroni; Charles C J Carpenter
Journal:  HIV Clin Trials       Date:  2004 Nov-Dec

6.  Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.

Authors:  John G Gerber; Susan L Rosenkranz; Carl J Fichtenbaum; Jose M Vega; Amy Yang; Beverly L Alston; Susan W Brobst; Yoninah Segal; Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

7.  Visceral abdominal-fat accumulation associated with use of indinavir.

Authors:  K D Miller; E Jones; J A Yanovski; R Shankar; I Feuerstein; J Falloon
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245

10.  Lung cancer in humans is not associated with lifetime total alcohol consumption or with genetic variation in alcohol dehydrogenase 3 (ADH3).

Authors:  Jo L Freudenheim; Malathi Ram; Jing Nie; Paola Muti; Maurizio Trevisan; Peter G Shields; Elisa V Bandera; Lucy A Campbell; Susan E McCann; Holger J Schunemann; Anne Marie Carosella; Dominica Vito; Marcia Russell; Thomas H Nochajski; Radoslav Goldman
Journal:  J Nutr       Date:  2003-11       Impact factor: 4.798

View more
  9 in total

1.  The impact of long-term moderate and heavy alcohol consumption on incident atherosclerosis among persons living with HIV.

Authors:  N E Kelso-Chichetto; M Plankey; D S Sheps; A G Abraham; X Chen; S Shoptaw; R C Kaplan; W S Post; R L Cook
Journal:  Drug Alcohol Depend       Date:  2017-10-28       Impact factor: 4.492

Review 2.  The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review.

Authors:  Natalie E Kelso; David S Sheps; Robert L Cook
Journal:  Am J Drug Alcohol Abuse       Date:  2015-07-30       Impact factor: 3.829

3.  Low cholesterol? Don't brag yet ... hypocholesterolemia blunts HAART effectiveness: a longitudinal study.

Authors:  María Jose Míguez; John E Lewis; Vaughn E Bryant; Rhonda Rosenberg; Ximena Burbano; Joel Fishman; Deshratn Asthana; Rui Duan; Nair Madhavan; Robert M Malow
Journal:  J Int AIDS Soc       Date:  2010-07-13       Impact factor: 5.396

4.  HAART-associated dyslipidemia varies by biogeographical ancestry in the multicenter AIDS cohort study.

Authors:  Matthew J Nicholaou; Jeremy J Martinson; Alison G Abraham; Todd T Brown; Shehnaz K Hussain; Steven M Wolinsky; Lawrence A Kingsley
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-08       Impact factor: 2.205

5.  Cholesterol as a Mediator of Alcohol-Induced Risks for Respiratory Disease Hospitalizations among People Living With HIV.

Authors:  María José Míguez; Rhonda Rosenberg; Ximena Burbano; Robert Malow
Journal:  J AIDS Clin Res       Date:  2011-10-21

6.  Effects of PPARγ and RBP4 gene variants on metabolic syndrome in HIV-infected patients with anti-retroviral therapy.

Authors:  Yuan-Pin Hung; Nan-Yao Lee; Sheng-Hsiang Lin; Ho-Ching Chang; Chi-Jung Wu; Chia-Ming Chang; Po-Lin Chen; Hsiao-Ju Lin; Yi-Hui Wu; Pei-Jane Tsai; Yau-Sheng Tsai; Wen-Chien Ko
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

7.  Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia.

Authors:  Amit C Achhra; Janaki Amin; Jennifer Hoy; Junko Tanuma; Thira Sirisanthana; David Nolan; Tuti Merati; Michelle Giles
Journal:  AIDS Res Treat       Date:  2012-05-14

8.  Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV.

Authors:  Manuela G Neuman; Michelle Schneider; Radu M Nanau; Charles Parry
Journal:  AIDS Res Treat       Date:  2012-03-11

Review 9.  Alcohol's role in HIV transmission and disease progression.

Authors:  Ivona Pandrea; Kyle I Happel; Angela M Amedee; Gregory J Bagby; Steve Nelson
Journal:  Alcohol Res Health       Date:  2010
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.